Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.66 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11188347 | 0.90 | L3MBTL1 (0.55) | L3MBTL1APEX1KMT2AMEN1 | |
| SCHEMBL11177999 | 0.85 | KMO (0.49) | L3MBTL1 | |
| SCHEMBL11181973 | 0.83 | ALDH1A1 (0.57) | L3MBTL1ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL13912958 | 0.82 | LYN (0.50) | — | |
| SCHEMBL6279039 | 0.80 | L3MBTL1 (0.59) | L3MBTL1APEX1KMT2AMEN1KDM4E | |
| SCHEMBL11191874 | 0.80 | MAPT (0.52) | L3MBTL1KDM4E | |
| SCHEMBL6689677 | 0.80 | L3MBTL1 (1.00) | L3MBTL1APEX1ALDH1A1KMT2AKDM4E | |
| SCHEMBL18523574 | 0.78 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1KMT2AMEN1KDM4E | |
| SCHEMBL11178545 | 0.77 | ALDH1A1 (0.50) | L3MBTL1ALDH1A1KMT2AKDM4E | |
| SCHEMBL18537230 | 0.77 | BTK (0.55) | L3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| EP-2004193-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007108968-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-4395414-A | Substituted quinolinone-alkanecarboxylic acids and medicaments containing them, having a hyperglycaemic action | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-07-26 | — | — | US | disclosed |
| EP-0024638-A1 | Substituted quinolinone-alkanecarboxylic acids, their preparation, and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1981-03-11 | — | — | EP | disclosed |
| WO-1981000564-A1 | SUBSTITUTED QUINOLINONE-ALKANECARBOXYLIC ACIDS,THEIR PREPARATION AND USE,AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1981-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | L3MBTL1 4741/4885APEX1 3671/4885ALDH1A1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.